Terapevticheskii arkhiv · 1999
[Experience in long-term use of berodual in the treatment of patients with chronic obstructive bronchitis].
Клиническое исследованиеСравнительное исследованиеАннотация на английскомСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Shmelev E I, Khmel'kova N G, Nonikov D V, Melent'eva E M, Abubikirov A F, Makarova V L, Mazaeva L A, Ushakova T I
Аннотация
AIM: To study clinical efficiency of 12-month administration of berodual in chronic obstructive bronchitis (COB).
MATERIALS AND METHODS: The trial entered 33 patients with at least 2-year history of COB and forced expiratory volume per 1 sec (FEV1) not less than 45% of normal value.
RESULTS: The best response of clinical parameters and external respiration was observed throughout 3 weeks of berodual inhalations. Dyspnea and cough were cured by the end of the treatment in 40 and 26% of the patients, respectively. Exercise tolerance has improved, FEV1 has increased for the year from 71.9 to 79.1%.
CONCLUSION: Long-term berodual monotherapy is able to inhibit progression of bronchial obstruction and symptoms of COB.
MATERIALS AND METHODS: The trial entered 33 patients with at least 2-year history of COB and forced expiratory volume per 1 sec (FEV1) not less than 45% of normal value.
RESULTS: The best response of clinical parameters and external respiration was observed throughout 3 weeks of berodual inhalations. Dyspnea and cough were cured by the end of the treatment in 40 and 26% of the patients, respectively. Exercise tolerance has improved, FEV1 has increased for the year from 71.9 to 79.1%.
CONCLUSION: Long-term berodual monotherapy is able to inhibit progression of bronchial obstruction and symptoms of COB.